Company research
Stereotaxis, Inc.
CIK 1289340Updated Sep 24, 2026
SecuritySTXS · NYSE_AMERICAN · equity
STXS price & chart
Loading TradingView…
AMEX:STXS on TradingView ↗In the news
University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program ↗
Recent filings
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
Other Events
Items 8.01, 9.01
S-3 filing
S-3 filing
Unregistered Sales of Equity Securities · Regulation FD Disclosure · Other Events
Items 3.02, 7.01, 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 52,251,000Source | 46,724,000Source | 41,909,000Source | 53,413,000Source |
| Property, Plant and Equipment, NetUSD | 3,019,000Source | 3,573,000Source | 3,304,000Source | 3,831,000Source |
| GoodwillUSD | 3,764,000Source | 3,764,000Source | — | — |
| Intangible Assets, Net (Excluding Goodwill)USD | — | 7,358,000Source | — | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 13,421,000Source | 12,217,000Source | 19,818,000Source | 8,586,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 5,847,000Source | 3,824,000Source | 3,822,000Source | 5,090,000Source |
| Inventory, NetUSD | 9,567,000Source | 8,331,000Source | 8,426,000Source | 7,876,000Source |
| Assets, CurrentUSD | 33,849,000Source | 26,439,000Source | 33,267,000Source | 43,246,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 698,000Source | 1,848,000Source | 676,000Source | 1,325,000Source |
| Operating Lease, Right-of-Use AssetUSD | 4,912,000Source | 5,483,000Source | 4,982,000Source | 5,384,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 33,530,000Source | 35,292,000Source | 19,989,000Source | 21,484,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | — | — | 6,000Source |
| Common Stock, Value, IssuedUSD | 95,000Source | 85,000Source | 81,000Source | 75,000Source |
| Additional Paid in CapitalUSD | 596,960,000Source | 567,926,000Source | 554,148,000Source | 543,438,000Source |
| Retained Earnings (Accumulated Deficit)USD | -583,368,000Source | -561,725,000Source | -537,680,000Source | -516,967,000Source |
| Stockholders' Equity Attributable to ParentUSD | 13,481,000Source | 6,080,000Source | 16,343,000Source | 26,346,000Source |
| Liabilities and EquityUSD | 52,251,000Source | 46,724,000Source | 41,909,000Source | 53,413,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 22,360,000Source | 21,602,000Source | 13,247,000Source | 14,291,000Source |
| Operating Lease, Liability, CurrentUSD | 642,000Source | 570,000Source | 428,000Source | 373,000Source |
| Accounts Payable, CurrentUSD | 4,768,000Source | 5,668,000Source | 3,190,000Source | 3,270,000Source |
| Operating Lease, Liability, NoncurrentUSD | 4,794,000Source | 5,436,000Source | 5,062,000Source | 5,488,000Source |
| Other Liabilities, NoncurrentUSD | 1,097,000Source | 64,000Source | 43,000Source | 51,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 2,065,000Source | 2,922,000Source | 2,972,000Source | 3,306,000Source |
| Short-term InvestmentsUSD | — | — | — | 19,844,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 9,852,000Source | 10,262,000Source | 10,623,000Source | 10,576,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 2,023,000Source | -691,000Source | -1,268,000Source | -316,000Source |
| Increase (Decrease) in InventoriesUSD | 1,236,000Source | -677,000Source | 550,000Source | 2,906,000Source |
| Increase (Decrease) in Accounts PayableUSD | -880,000Source | 758,000Source | 218,000Source | -169,000Source |
| Deferred Income Tax Expense (Benefit)USD | 2,198,000Source | 2,199,000Source | 2,881,000Source | 2,083,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -13,685,000Source | -8,497,000Source | -9,139,000Source | -8,415,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -93,000Source | 74,000Source | 19,765,000Source | -22,094,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 14,763,000Source | 297,000Source | 81,000Source | 220,000Source |
| Payments of Ordinary Dividends, Common StockUSD | 0Source | 0Source | 0Source | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 985,000Source | -8,126,000Source | 10,707,000Source | -30,289,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 13,421,000Source | — | 20,562,000Source | 9,855,000Source |
| Additional Financial Items | ||||
| AmortizationUSD | — | 382,000Source | — | — |
| Amortization of Intangible AssetsUSD | 929,000Source | 400,000Source | — | — |
| DepreciationUSD | 626,000Source | 587,000Source | 595,000Source | 429,000Source |
| General and Administrative ExpenseUSD | 17,849,000Source | 17,201,000Source | 14,050,000Source | 14,363,000Source |
| GoodwillUSD | 3,764,000Source | 3,764,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -21,643,000Source | -24,045,000Source | -20,713,000Source | -18,292,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -22,914,000Source | -25,353,000Source | -22,056,000Source | -19,635,000Source |
| Operating ExpensesUSD | 39,183,000Source | 39,333,000Source | 36,699,000Source | 37,246,000Source |
| Operating Lease, ExpenseUSD | 1,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | 2,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | 15,656,000Source | 297,000Source | 81,000Source | 220,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 32,377,000Source | 26,918,000Source | 26,771,000Source | 28,147,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Operating Income (Loss)USD | -22,112,000Source | -24,739,000Source | -21,839,000Source | -18,776,000Source |
| Other Nonoperating Income (Expense)USD | 2,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -21,643,000Source | -24,045,000Source | -20,713,000Source | -18,292,000Source |
| Earnings Per Share, BasicUSD per share | -0.25Source | -0.3Source | -0.27Source | -0.26Source |
| Earnings Per Share, DilutedUSD per share | -0.25Source | -0.3Source | -0.27Source | -0.26Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 90,957,313Source | 85,183,306Source | 80,702,358Source | 76,061,183Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 90,957,313Source | 85,183,306Source | 80,702,358Source | 76,061,183Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 929,000Source | 400,000Source | — | — |
| Business Combination, Acquisition Related CostsUSD | — | 451Source | — | — |
| General and Administrative ExpenseUSD | 17,849,000Source | 17,201,000Source | 14,050,000Source | 14,363,000Source |
| Gross ProfitUSD | 17,071,000Source | 14,594,000Source | 14,860,000Source | 18,470,000Source |
| Interest Income (Expense), NetUSD | 467,000Source | 694,000Source | 1,096,000Source | 484,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -22,914,000Source | -25,353,000Source | -22,056,000Source | -19,635,000Source |
| Operating ExpensesUSD | 39,183,000Source | 39,333,000Source | 36,699,000Source | 37,246,000Source |
| Operating Lease, ExpenseUSD | 1,000Source | — | — | — |
| Other IncomeUSD | — | — | 30,000Source | — |
| Preferred Stock Dividends, Income Statement ImpactUSD | 1,271,000Source | 1,308,000Source | 1,343,000Source | 1,343,000Source |
| Research and Development ExpenseUSD | 9,383,000Source | 9,760,000Source | 10,273,000Source | 10,558,000Source |
| Selling and Marketing ExpenseUSD | 12,443,000Source | 12,372,000Source | 12,376,000Source | 12,325,000Source |
Filing attachments
ex99-1.htm · 8-K · 2026-08-11
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates Robotic catheter revenue surpasses $1M in the quarter, growing 270% sequentially First GenesisX robotic system purchase by US hospital to be installed this fall Multiple Synchrony digital operating room systems sold and installed following FDA clearance in April Completed previously announced acquisition of Robocath, strengthening robotic technology leaders…
Read attachment ↗ex99-1.htm · 8-K · 2026-07-16
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 RISK FACTORS Risks Related to our Recently Completed Acquisition of Robocath We may be unable to successfully integrate Robocath into our business and may fail to realize any or all of the anticipated benefits of the acquisition, or those benefits may take longer to realize than expected. Prior to the completion of our acquisition of Robocath, both companies previously operated independently and manufactured different products. The success of the…
Read attachment ↗ex99-1.htm · 8-K · 2026-07-09
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Stereotaxis Completes Acquisition of Robocath St. Louis, USA & Rouen, France, July 9, 2026 (Globe Newswire) - Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has completed its previously announced acquisition of Robocath, an innovator of robotic technologies for interventional cardiology and neurointerventions. Robocath will now be fully integrated…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-12
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates Proprietary robotically-navigated MAGiC catheter received U.S. FDA approval in January and is now being utilized at multiple sites across the United States as well as Europe Synchrony digital operating room system received U.S. FDA clearance in April and initial orders and shipments are ongoing ───────────────────────────────────────────────────────────────────…
Read attachment ↗ex99-1.htm · 8-K · 2026-03-09
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Stereotaxis Reports 2025 Full Year Financial Results St. Louis, MO, March 9, 2026 (Globe Newswire) - Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2025. “The past year saw tremendous progress with significant regulatory approvals globally, advancement of a broad pipeline of innovati…
Read attachment ↗